Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403385 · ClinicalTrials.gov registry record · Phase 2
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
A Phase 2 study of Metastatic NSCLC - Non-Small Cell Lung Cancer and Locally Advanced NSCLC - Non-Small Cell Lung Cancer, sponsored by iTeos Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 20
- Study locations
NCT05403385: Active Phase 2 study of Metastatic NSCLC - Non-Small Cell Lung Cancer and Locally Advanced NSCLC - Non-Small Cell Lung Cancer, sponsored by iTeos Therapeutics.
NCT05403385 is a Phase 2 study of Metastatic NSCLC - Non-Small Cell Lung Cancer and Locally Advanced NSCLC - Non-Small Cell Lung Cancer that is active but no longer recruiting, run by iTeos Therapeutics. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05403385, a Phase 2 study of Metastatic NSCLC - Non-Small Cell Lung Cancer and Locally Advanced NSCLC - Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by iTeos Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.
Primary Outcome
Incidence of dose-limiting toxicities
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Pemetrexed
- DRUG inupadenant
Study Locations (20)
Other
- Algemeen Ziekenhuis Sint-Lucas - Ghent
- Jessa Ziekenhuis - Hasselt
- AZ Delta - Roeselare
- Vseobecna Fakultni Nemocnice - Prague
- CHU de Caen - Caen
- Hopital de la Timone Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM) - Marseille
- CHU Nantes - Nantes
- Istituto Nazionale dei Tumori - Milan
- Gruppo Humanitas - Istituto Clinico Humanitas - Rozzano
- Centro Oncologico de Galicia - A Coruña
- Hospital Infanta Cristina (Hospital Universitario de Badajoz) - Badajoz
- Hospital Universitario Vall d'Hebron - Barcelona
- Althaia Hospital - Manresa
- Complejo Hospitalario Universitario de Ourense - Ourense
Arkansas
- Highlands Oncology Group - Fayetteville
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Ontario
- William Osler Health System - Brampton
Balearic Islands
- Hospital Universitari Son Espases - Palma de Mallorca
Pamplona
- Complejo Hospitalario de Navarra (CHN) - Pamplona
Valencia
- Hospital Universitari i Politecnic La Fe de Valencia - Valencia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2025-10 |
| Phase | Phase 2 |
What the registry record for NCT05403385 still lists
NCT05403385 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Metastatic NSCLC - Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT05403385 names 20 study sites across 7 states, led by Other, Arkansas, Florida.
Frequently Asked Questions
What is clinical trial NCT05403385 about?
NCT05403385 is a clinical study titled "Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer". The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combina...
What is the current status of trial NCT05403385?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-08-26. Estimated completion is 2025-10.
What conditions does trial NCT05403385 study?
This clinical trial studies the following conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05403385?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Pemetrexed (DRUG), inupadenant (DRUG).
Who is sponsoring clinical trial NCT05403385?
This trial is sponsored by iTeos Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05403385 being conducted?
This trial has 20 study locations across Arkansas, Florida, Ontario, Balearic Islands, Pamplona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic NSCLC - Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05403385's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI